MedTrace Logo

Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose

NCT03243903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2020-03-27

No results posted yet for this study

Summary

In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients（T2DM）.The efficacy and safety of QS-M needle-free injector and needle-insulin pen were evaluated and compared.This is a needle-insulin pen as control group, using a prospective, multicenter, randomized, open, parallel grouping study.

Conditions

Interventions

DEVICE

QS-M insulin-free injector

Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.

DEVICE

conventional insulin pen

Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.

Sponsors & Collaborators

  • Beijing QS Medical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ji Li Nong · Peking University People 's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-18
Primary Completion
2018-11-08
Completion
2018-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03243903 on ClinicalTrials.gov